Pharsight

Xerese patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39264 BAUSCH Pharmaceutical combination
Feb, 2016

(8 years ago)

US6514980 BAUSCH Nucleoside analogs in combination therapy of herpes simplex infections
Jan, 2017

(7 years ago)

US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Feb, 2021

(3 years ago)

Xerese is owned by Bausch.

Xerese contains Acyclovir; Hydrocortisone.

Xerese has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Xerese are:

  • USRE39264
  • US6514980
  • US7223387

Xerese was authorised for market use on 31 July, 2009.

Xerese is available in cream;topical dosage forms.

Xerese can be used as new combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older).

The generics of Xerese are possible to be released after 28 February, 2021.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jan 22, 2017
New Combination(NC) Jul 31, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...

Dosage: CREAM;TOPICAL

More Information on Dosage

XERESE family patents

Family Patents